Authors
Latest:
Patient-Derived Xenografts Could Improve Precision Medicine OutcomesResearchers at the UC Davis Comprehensive Cancer Center are personalizing treatment using tumor xenografts in mice to test and identify more precise treatments for bladder cancer patients.
Latest:
Unmet Needs and Future Perspectives in Treatment of MDSExpert oncologists discuss unmet needs and share final thoughts on the future of treatment of patients with lower-risk MDS.
Latest:
Dr. Srinivasan on the Challenges of Developing New Therapies in Rare RCC SubtypesRamaprasad Srinivasan, MD, PhD, discusses the challenges of developing new therapies to treat patients with rare renal cell carcinoma subtypes.
Latest:
Dr. Govindan on the Future of EGFR-Mutant NSCLCRamaswamy Govindan, MD, professor, Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in St. Louis, discusses the future treatment landscape of EGFR-mutant non–small cell lung cancer (NSCLC).
Latest:
Dr. Govindan on the Phase I Results of AMG 510 Evaluated in NSCLCRamaswamy Govindan, MD, professor of medicine, Washington University School of Medicine discusses the results of a phase I study looking at safety, tolerability, pharmacokinetics, and efficacy of KRAS G12C inhibitor, AMG 510 in patients with non-small cell lung cancer.
Latest:
Dr. Ramanathan Discusses the Treatment of Pancreatic CancerRamesh K. Ramanathan, MD, director, Gastrointestinal Medical Oncology Program, Mayo Clinic, discusses the treatment of patients with pancreatic cancer.
Latest:
Dr Eskander on Pembrolizumab Plus Chemo in Advanced/Recurrent Endometrial CancerRamez N. Eskander, MD, discusses overall survival data for pembrolizumab plus chemotherapy in advanced/recurrent endometrial cancer.
Latest:
Dr Komrokji on the Potential Implications of the COMMANDS trial in MDSRami Komrokji, MD, shares the potential clinical implications of data from the phase 3 COMMANDS trial of luspatercept in patients with very low– to intermediate-risk myelodysplastic syndromes who have not received prior treatment with an erythropoiesis-stimulating agents.
Latest:
Dr Komrokji on Ongoing Investigations With Luspatercept in MDSRami Komrokji, MD, discusses the benefit of agents such as luspatercept-aamt in patients with very low– to intermediate-risk myelodysplastic syndromes who have not received prior treatment with erythropoiesis-stimulating agents.
Latest:
Dr. Garcia-Sanz on Combination Chemotherapy for Relapsed/Refractory Hodgkin LymphomaRamon Garcia-Sanz, MD, PhD, clinician, department of Hematology, Hospital Universitario de Salamanca, discusses combination chemotherapy in patients with Hodgkin lymphoma.
Latest:
Dr. Dadu on Treatment Options for Thyroid CancerRamona Dadu, MD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment options for patients with anaplastic thyroid cancer.
Latest:
Resection and Reconstruction of a Solitary Sternal Metastasis After Mastectomy for Breast Cancer: A Case Report and Review of the LiteratureIn May 2005, a 25-year-old female presented to her primary care physician complaining of a newly palpable breast mass that had grown to several centimeters over the course of a few months.
Latest:
Something Good Happened Today: An Oncology Fellow ReflectsRamy Sedhom, MD, looks back on his first year of oncology fellowship and shares advice for first-year fellows and trainees.
Latest:
Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate CancerOur expert panel provide insightful discussion on the power of multidisciplinary expertise in advanced prostate cancer.
Latest:
CAR T-Cell Therapy in Metastatic CRPC and Future Directions in CareClosing out their final module, expert panelists consider the role of CAR T-cell therapy in metastatic castration-resistant prostate cancer and look toward future evolutions in the broader treatment landscape.
Latest:
Dr. Henderson on Accessibility of Proton Therapy in Prostate CancerRandal H. Henderson, MD, MBA, discusses accessibility of proton therapy versus intensity-modulated radiation therapy in prostate cancer.
Latest:
Dr. Randal Weber on Future Treatment Approaches for Patients With MelanomaRandal S. Weber, MD, FACS, professor, department chair, John Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer Medicine, Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses future treatment approaches for patients with melanoma.
Latest:
Dr. Oyer on Tools for Clinicians to Use When Treating Patients With CancerRandall A. Oyer, MD, oncology program, medical director, Lancaster General Health, treasurer, Association of Community Cancer Centers, discusses some of the tools clinicians could potentially use for their patients with cancer.
Latest:
Dr. Holcombe on the Utility of Stool DNA Test for Colon CancerRandall F. Holcombe, MD, professor, Chief Medical Officer, Cancer, Mount Sinai Health System, discusses key takeaways for a practicing oncologist regarding the stool DNA test for colon cancer.
Latest:
The Role of the Provider in Policy ReformRandy Burkholder, vice president, Policy & Research, PhRMA, discusses the role that providers play in policy reform.
Latest:
The Clinical and Economic Value of Rituximab for the Treatment of Hematologic MalignanciesRituximab is a humanized monoclonal antibody that is used for the treatment of a wide variety of B-cell-derived hematologic malignancies
